Manuel Hidalgo, MD, PhD
Investigators are evaluating whether eryaspase (Graspa), an L-asparaginase-based therapy that triggers tumor cell death, can extend survival for patients with pancreatic cancer. Patients with advanced pancreatic adenocarcinoma have few effective treatment options outside of a clinical trial or palliative care,1
and this could solve an unmet medical need.
Figure. Eryaspase in Patients With Advanced Pancreatic Cancer
“The beautiful thing about the trial is that eryaspase can be given with either gemcitabine/abraxane- or irinotecan-based chemotherapy, which means that it could be more broadly applicable to the patient population,” Hidalgo said.
... to read the full story